Jupiter Endovascular

Jupiter Endovascular is a medical technology company located in Menlo Park, California. The company focuses on innovating treatments for cardiovascular diseases using its unique Endoportal Control™ platform. This technology aims to merge the precision of surgical procedures with the simplicity of catheter-based interventions, specifically targeting pulmonary embolism (PE), a significant market opportunity. The flagship product, the Vertex Pulmonary Embolectomy System, utilizes the Endoportal Control™ technology to provide precise positioning within the vasculature. This system allows for stable access to treat blood clots in the lungs, enhancing procedural safety and effectiveness. Jupiter Endovascular is currently conducting a pivotal clinical trial, SPIRARE II, approved by the U.S. FDA, to assess the safety and efficacy of the Vertex system in patients with acute, intermediate-risk pulmonary embolism. The company has raised $21 million to support its clinical development and commercialization efforts. Its leadership team includes experienced professionals in product development, clinical affairs, regulatory affairs, and manufacturing. Jupiter Endovascular serves interventional cardiologists and vascular specialists looking for advanced endovascular treatment options.

• Employees 45